Lopinavir exposure with an increased dose during pregnancy

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 5, 2008, Pages 485-491

  Mirochnick, Mark ^a,i   Best, Brookie M ^b   Stek, Alice M ^c   Capparelli, Edmund ^b   Hu, Chengcheng ^d   Burchett, Sandra K ^e   Holland, Diane T ^b   Smith, Elizabeth ^f   Gaddipati, Sreedhar ^g   Read, Jennifer S ^h  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g New York Presbyterian Columbia University Medical Center   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ BOSTON MEDICAL CENTER   (United States)

Author keywords

HIV lopinavir; Mother to child transmission; Pharmacokinetics; Pregnancy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOTHER CHILD RELATION; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SECOND TRIMESTER PREGNANCY; STEADY STATE; THIRD TRIMESTER PREGNANCY; ADOLESCENT; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; MULTICENTER STUDY; PREGNANCY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PYRIMIDINONES; RITONAVIR; YOUNG ADULT;

EID: 62749098712     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318186edd0     Document Type: Article

References (18)

1. Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery and viral load in 2895 US women (PACTG 367). Paper presented at: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 10, 2004; San Francisco, CA. Abstract 99.
2. Public Health Service Task Force: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. July 8, 2008. Available at: http://aidsinfo.nih.gov/guidelines. Accessed October 16, 2008.
3. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071-1087.
4. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939.
5. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:Fl-9.
6. The Division of AIDS (DAIDS) standardized Toxicity Table for Grading Severity of Adult Adverse Experiences, August 1992. Available at: http:// rcc.tech-res-intl.com. Accessed October 16, 2008.
7. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824-831.
8. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS. 2007;21:643-645.
9. Lyons F, Lechelt M, Magaya V, et al. Adequate trough lopinavir levels with standard dosing in pregnancy. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO. Abstract 709.
10. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS. 2007;21:1053-1054.
11. Kaletra (product labeling) [package insert], Abbott Laboratories, Abbott Park, IL; 2005.
12. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet. 1982;7:336-352.
13. Krauer B, Dayer P, Anner R. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetalmaternal pairs. Br J Obstet Gynaecol. 1984;91:875-881.
14. Aweeka FT, Stek A, Best B, et al, for the P1026s team. Lopinavir protein binding during pregnancy. Presented at: The 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles, CA. Abstract 787.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed October 16, 2008.
16. Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2005;49:1720-1726.
17. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004;18:1305-1310.
18. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002; 46:2926-2932.